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ABSTRACT 20 
Respiratory syncytial virus (RSV) is a top cause of severe lower respiratory tract disease 21 
and mortality in infants and the elderly. Currently, no vaccine or effective treatment 22 
exists for RSV. The RSV G glycoprotein mediates viral attachment to cells and 23 
contributes to pathogenesis by modulating host immunity through interactions with the 24 
human chemokine receptor CX3CR1. Antibodies targeting the RSV G central conserved 25 
domain are protective in both prophylactic and post-infection animal models. Here we 26 
describe the crystal structure of the broadly-neutralizing human monoclonal antibody 27 
3G12 bound to the RSV G central conserved domain. Antibody 3G12 binds to a 28 
conformational epitope composed of highly conserved residues, explaining its broad 29 
neutralization activity. Surprisingly, RSV G complexed with 3G12 adopts a distinct 30 
conformation not observed in previously described RSV G–antibody structures. 31 
Comparison to other structures reveals that the RSV G central conserved domain is 32 
flexible and can adopt multiple conformations in the regions flanking the cysteine noose. 33 
We also show that restriction of RSV G flexibility with a proline mutation abolishes 34 
binding to antibody 3G12 but not antibody 3D3, which recognizes a different 35 
conformation of RSV G. Our studies provide new insights for rational vaccine design, 36 
indicating the importance of preserving both the global structural integrity of antigens 37 
and local conformational flexibility at antigenic sites, which may elicit a more diverse 38 
antibody response and broader protection against infection and disease.  39 
IMPORTANCE 40 
Respiratory syncytial virus (RSV) causes severe respiratory infections in infants, young 41 
children, and the elderly, and currently no licensed vaccine exists. In this study, we 42 
describe the crystal structure of the RSV surface glycoprotein G in complex with a 43 
broadly-neutralizing human monoclonal antibody. The antibody binds to RSV G at a 44 
highly conserved region stabilized by two disulfide bonds, but it captures RSV G in a 45 
conformation not previously observed, revealing that this region is both structured and 46 
flexible. Importantly, our findings provide insight for the design of vaccines that elicit 47 
diverse antibodies, which may provide broad protection from infection and disease.   48 
INTRODUCTION   49 
Respiratory syncytial virus (RSV) is a globally prevalent virus that affects the 50 
airways and lungs. Infants and young children are at the highest risk of severe outcome 51 
from RSV infection, with 33.1 million episodes of lower respiratory tract infection and 52 
approximately 3.2 million hospital visits and 118,200 deaths per year worldwide in 53 
children under age 5 due to RSV (1). RSV is also a major cause of illness in adults older 54 
than 65 years and immunocompromised individuals, with an estimated 14,000 deaths per 55 
year in the United States (2). Hospitalization due to RSV is a major economic burden, 56 
especially in preterm infants and older adults (3).   57 
Currently, no licensed vaccine exists for the prevention of RSV infection, making 58 
RSV one of the highest burden diseases with no readily available preventative measure. 59 
The only FDA-approved therapy for RSV is passive prophylaxis with palivizumab 60 
(Synagis), a monoclonal antibody, which reduces disease severity and hospitalization (4). 61 
Palivizumab’s approved use is limited to high-risk premature birth infants; moreover, the 62 
high cost, approximately $10,000, for a full course of therapy, limits use even in that 63 
narrow indication (5). The need for widely available vaccines and therapies for RSV is 64 
evidenced from the 19 vaccine candidates and therapeutic monoclonal antibodies in 65 
clinical trials (6). 66 
RSV is a negative-sense single stranded RNA virus with two major glycoproteins 67 
on the virion surface: the attachment glycoprotein (G) and the fusion glycoprotein (F) (7). 68 
RSV G is responsible for cellular attachment to host cells and RSV F causes the viral 69 
membrane to fuse with the target host cell membrane. While both RSV F and G are 70 
immunogenic and are targeted by neutralizing antibodies, the majority of neutralizing 71 
antibodies in human sera target RSV F (8, 9). As such, most RSV vaccine candidates and 72 
therapeutic antibodies currently in development focus on RSV F. However, RSV that 73 
does not express the G protein is highly attenuated in vivo (10), and monoclonal 74 
antibodies that target RSV G are protective in vivo (11-21). In humans, anti-G antibodies 75 
are associated with lower clinical disease severity scores, despite an abundance in sera 76 
more than 30 times lower than anti-F antibodies (8). Thus, the RSV G protein is 77 
increasingly recognized as an important target for RSV vaccine and therapeutic antibody 78 
development (22). 79 
 RSV G is a type II membrane protein containing two mucin-like regions coated 80 
with 30-40 O-linked glycans and 3-5 N-linked glycans (Fig. 1A) (7, 23, 24). There are 81 
two forms of RSV G produced during infection. Membrane-bound RSV G is responsible 82 
for virus attachment to airway epithelial cells via the human chemokine receptor 83 
CX3CR1 (25-28). A secreted form of RSV G, derived from a second translation initiation 84 
site at Met48 and released from the membrane by proteolysis, is expressed early in 85 
infection (first ~6 hours, prior to the release of virions at ~12 hours) (Fig. 1A) (29). 86 
Secreted RSV G modulates signaling and trafficking of CX3CR1
+
 immune cells, 87 
contributing to airway congestion and pathogenesis (26, 27, 30-33). Between the two 88 
mucin-like regions of RSV G is a central conserved domain (CCD) of ~40 highly 89 
conserved amino acids, including four invariant cysteines forming a cysteine noose motif 90 
with two disulfide bonds (1-4, 2-3 connectivity) (Fig. 1A) (34-36). While the C-terminus 91 
of the RSV G CCD possesses a heparin binding domain (Fig. 1A) (37, 38), initial RSV 92 
infection is thought to be mediated primarily by interaction between the RSV G CCD and 93 
CX3CR1 on ciliated airway cells (25-28), which do not have measurable heparan sulfate 94 
proteoglycans on their surfaces (39).  95 
 Broadly neutralizing monoclonal antibodies (bnmAbs) that target RSV G are able 96 
to neutralize RSV infectivity in cell culture, including in HAE cells, and significantly 97 
reduce RSV viral loads and disease in both prophylactic and post-infection animal 98 
models (12, 14-16, 21, 25, 28, 40, 41). In addition, treatment with anti-RSV G mAbs 99 
reduces BAL cell influx including RSV G protein-induced leukocyte migration and 100 
eosinophilic inflammatory response, resulting in decreased airway congestion (15, 33, 101 
42). Anti-G mAbs have also been shown to reduce mucus production and to restore 102 
beneficial antiviral IFN-α (18, 42-44). Most of the anti-G bnmAbs that have been studied 103 
to date bind with high affinity to RSV G (KD (dissociation constant) = 1.1 pm - 3.3 nM) 104 
and bind to linear epitopes within the RSV G CCD as determined by linear epitope 105 
mapping techniques (17, 21, 40, 45). Recently, two studies elucidated four high-106 
resolution crystal structures of antibody-RSV G CCD complexes (16, 46). Unexpectedly, 107 
all four antibodies have additional interactions outside their linear epitopes, revealing a 108 
previously unappreciated role of the disulfide-stabilized cysteine noose in forming 109 
conformational epitopes and contributing to high-affinity antibody binding. 110 
Here we investigated the human bnmAb 3G12, which reduces viral loads, airway 111 
hyper-responsiveness, and inflammation in both prophylactic and post-infection mouse 112 
models of RSV infection (12, 21). Linear epitope mapping experiments have shown that 113 
bnmAb 3G12 binds to RSV G CCD residues 167-176, which is shifted downstream 114 
compared to other anti-G bnmAbs in the panel that bind primarily RSV G residues 162-115 
169 (12, 21). We hypothesized that structural studies into the 3G12 epitope might reveal 116 
additional information about the mechanisms of high-affinity antibody binding and broad 117 
neutralization against RSV A and B strains. We present here the structure of antibody 118 
3G12 bound to the RSV G CCD, which reveals a novel conformational epitope composed 119 
of highly conserved residues. Comparison to other structures highlights the flexible 120 
nature of the RSV G CCD. We further show that RSV G flexibility is important for 121 
binding by antibody 3G12. Overall, these studies have broad implications for vaccine 122 
antigen design. The studies highlight the importance of preserving antigen structural 123 
integrity and also maintaining flexibility in antigenic sites, in order to elicit a diverse 124 
antibody response.  125 
 126 
RESULTS 127 
Fab 3G12-RSV G
157-197
 complex structure 128 
We investigated bnmAb 3G12, a native human antibody that binds RSV G with 129 
high affinity, KD = 579 pM. Antibody 3G12 shows broadly neutralizing activity across 130 
diverse lab and clinical RSV strains (21). To understand the molecular basis for the broad 131 
reactivity of bnmAb 3G12 and to determine if it binds to a larger conformational epitope 132 
beyond that predicted by linear epitope mapping, we used X-ray crystallographic studies 133 
to determine the structure of bnmAb 3G12 bound to the RSV G CCD (Fig. 1A). Purified 134 
antigen-binding fragment (Fab) 3G12 was mixed with recombinant RSV G
157-197
, which 135 
formed a stable complex in solution. We crystallized the Fab 3G12-RSV G
157-197
 complex 136 
and determined its crystal structure to 2.9 Å resolution (Fig. 1B, Fig. 1C, and Table 1).  137 
The Fab 3G12-RSV G
157-197
 complex structure reveals a 924 Å
2
 epitope on the 138 
RSV G CCD, with 3G12 heavy chain burying 697 Å
2 
and the light chain burying 227 Å
2
 139 
of the epitope (Fig. 1B). Similar to RSV G-antibody structures determined previously 140 
(16, 46), antibody 3G12 binds to a conformational epitope comprising RSV G residues 141 
160-179, 182 and 189, revealing additional interactions beyond the linear epitope 142 
residues 167-176 (Fig. 1). Epitope residues are invariant or highly conserved (Fig. 1A), 143 
explaining the broad reactivity of bnmAb 3G12 for diverse RSV strains. The 3G12 heavy 144 
chain complementarity-determining regions (HCDRs) account for the majority of the 145 
interactions and buried surface with the RSV G CCD, with the HCDR2 burying the 146 
largest portion with 315 Å
2 
and HCDR3 accounting for 284 Å
2 
(Fig. 1C). On the light 147 
chain complementarity-determining regions (LCDRs), LCDR3 buries 169.5 Å
2
 on the N-148 
terminal end of the RSV G CCD, while LCDR1 and the Fab 3G12 N-terminal residues 149 
form additional minor interactions (Fig. 1C). The 3G12 heavy chain CDR2 stabilizes 150 
residues 167-170 of RSV G by several hydrogen bonds and van der Waals interactions 151 
(Fig. 1C). In addition, residues from all three of the HCDRs from bnmAb 3G12 stabilize 152 
hydrophobic interactions with RSV G residues F163, F165, F168, F170, P172, and I175, 153 
forming a hydrophobic core-like region within the antibody 3G12-RSV G complex (Fig. 154 
1C). Interestingly, the helix on the C-terminal end of the cysteine noose, which 155 
encompasses the CX3C motif (residues 180-186), has almost no interactions with 156 
antibody 3G12, unlike other antibody-RSV G CCD structures where this helix has a role 157 
in antibody binding (Fig. 1C and Fig. 2).  158 
 159 
RSV G CCD epitopes and conformational flexibility 160 
To better understand the conformational flexibility in the RSV G CCD, all known 161 
structures of the CCD bound by antibodies were compared (Fig. 2). The structures were 162 
aligned at the cysteine noose region (~ residues 170-187), which has an RMSD of <0.6 Å 163 
across all structures. The region N-terminal to the cysteine noose (~ residues 160-169) 164 
adopts a different conformation in each structure (RMSD of 3-5 Å) and varies in 165 
secondary structural elements (i.e. forms a helix when bound to antibody 3D3 and forms 166 
a strand when bound to antibody CB002.5)(Fig. 2). RSV G residue N169 appears to be 167 
flexible across all of the structures and may be one of the last ordered residues in the N-168 
terminal region of the CCD. Similarly, the C-terminal region after K187 may be flexible 169 
and capable of adopting multiple conformations (Fig. 2). These C-terminal non-170 
interacting RSV G CCD residues are present in most of the complexes but do not have 171 
visible electron density, suggesting that they are dynamic and flexible. Overall, the RSV 172 
G CCD cysteine noose is structurally conserved and is an important structural element for 173 
antibody binding, however the N- and C-terminal regions of the CCD are flexible and are 174 
captured in different conformations by diverse antibodies.  175 
 176 
Role of RSV G flexibility in bnmAb binding 177 
To evaluate the role of RSV G flexibility in bnmAb binding, we sought to 178 
investigate a mutant of RSV G with restricted flexibility in its CCD. We chose the mutant 179 
F170P, which was previously identified in neutralization escape mutants of respiratory 180 
syncytial virus grown in the presence of an anti-G monoclonal antibody (47). The F170 181 
side chain contributes only 1.3% of the 3G12 epitope (12 Å
2
 of the 924 Å
2
), suggesting 182 
that mutation of the side chain alone would not substantially affect bnmAb 3G12 binding. 183 
However, when bound to bnmAb 3G12, RSV G residue F170 has a Phi torsion angle of -184 
143 degrees, whereas a typical proline is restricted to a Phi torsion angle of -60 degrees. 185 
Thus, we reasoned that the proline mutation would restrict the flexibility of the RSV G 186 
CCD and could affect bnmAb binding. We produced and purified the wild-type RSV G 187 
ectodomain (RSV G
ecto
) and its mutant (RSV G
ecto
 F170P) (Fig. 3A). We then evaluated 188 
binding by bnmAbs 3G12 and 3D3, which bind to two very different conformations of 189 
the RSV G CCD (Fig. 3B). Biolayer interferometry binding studies reveal that while both 190 
bnmAbs bind to wild-type RSV G
ecto
 with high-affinity, bnmAb 3G12, but not 3D3, 191 
completely lost binding to the mutant RSV G
ecto
 F170P (Fig. 3C and Table 2). These data 192 
reveal that the mutant RSV G
ecto
 F170P can adopt the conformation for the 3D3 epitope, 193 
however it cannot adopt the conformation for the 3G12 epitope.  194 
 195 
DISCUSSION 196 
Our study highlights how even disulfide constrained antigens can have flexible, 197 
dynamic antigenic sites, and that different high-affinity antibodies can target these sites in 198 
distinct ways. We describe the crystal structure of the human bnmAb 3G12 bound to the 199 
RSV G CCD and show that bnmAb 3G12 binding is dependent on RSV G flexibility. The 200 
antibody binds to a conformational epitope composed of highly conserved residues, 201 
explaining its broad reactivity to diverse strains of RSV. The antibody interacts mainly 202 
with the RSV G CCD’s N-terminal region, in a conformation distinct from all other 203 
known CCD structures, suggesting that the RSV G CCD is flexible outside of its rigid 204 
disulfide bonded cysteine noose region. Residue N169 likely represents a ‘hinge’ residue, 205 
where the N-terminal region of the CCD preceding N169 appears to be flexible and 206 
capable of adopting multiple conformations and even secondary structures. Likewise, 207 
residues after K187 in the C-terminal region of the CCD also appear to be flexible. Thus, 208 
RSV G is part of a growing list of antigens with flexible or intrinsically disordered 209 
regions (IDRs) that are targeted by antibodies (48-56). 210 
The observation of different conformations of RSV G CCD raises several 211 
important questions. Does RSV G move freely and randomly, and do our structures 212 
reveal momentary snapshots captured by antibody binding? What conformation does 213 
RSV G adopt when interacting with the human CX3CR1 receptor? We note that none of 214 
the conformations have any substantial tertiary structure stabilizing interactions within 215 
the CCD or clearly defined secondary structure. Therefore it is unlikely that RSV G 216 
assumes distinct conformations without additional external stabilizing interactions. One 217 
form of stabilization may come from the oligomerization state of RSV G. It has been 218 
previously suggested that RSV G exists as a trimer or tetramer (57, 58). The extensive 219 
glycosylation of RSV G in the mucin-like regions flanking the CCD may also restrict 220 
RSV G flexibility. It is also possible that RSV G interacts with RSV F on the virus 221 
surface, creating a quaternary structure that may limit RSV G to the defined structures 222 
like those captured by the antibodies discussed in this paper. Interestingly, in a RSV 223 
virus-like particle vaccine containing F and G, the conformation of F affected the 224 
immunogenicity of G (59). These factors may be important in the design of an RSV 225 
vaccine.  226 
Our study also has important implications for vaccine antigen design in a broader 227 
sense. Recently, there has been a trend to stabilize antigens based on structural analyses 228 
to elicit higher levels of neutralizing antibodies targeting specific epitopes, e.g. HIV 229 
gp120, influenza hemagglutinin, MERS-Coronavirus spike, human parainfluenza virus 230 
fusion protein, human metapneumovirus fusion protein, and RSV fusion protein (60-71). 231 
A common approach to antigen stabilization in many of the aforementioned studies 232 
involves the introduction of proline substitutions and disulfide bonds, which can stabilize 233 
by limiting polypeptide backbone mobility. However, antigen over-stabilization could 234 
limit the diversity of antibody responses. In support of this concept, we show that limiting 235 
flexibility of RSV G with a proline mutation abolishes the epitope for the high-affinity 236 
bnmAb 3G12. Thus, when designing stabilized antigens that display specific epitopes, 237 
one should also consider the benefits of preserving the native flexibility of antigenic sites, 238 
which may elicit a more diverse immune response and may offer better protection against 239 
virus escape (Fig. 4). Incorporating antibody repertoire analysis technologies during 240 
vaccine development could provide opportunities to evaluate antibody diversity that is 241 
elicited by stabilized antigens. 242 
 243 
MATERIALS AND METHODS 244 
Production of bnmAb 3G12 and Fab 3G12. Recombinant bnmAb 3G12 was produced 245 
by transient-transfection in CHO cells and purification by immobilized protein A, as 246 
described previously (21, 45). Fab 3G12 was generated by incubation of bnmAb 3G12 247 
with immobilized papain, followed by removal of the Fc fragment with immobilized 248 
protein A. Fab 3G12 was then purified by Superdex 200 size-exclusion chromatography 249 
in 10 mM Tris-HCl pH 8.0 and 150 mM NaCl.  250 
 251 
Expression and purification of RSV G
157-197
. A synthetic gene codon-optimized for E. 252 
coli encoding RSV G (strain A2) amino acids 157 to 197 (UniProtKB entry P03423) with 253 
a C-terminal 6× histidine purification tag was cloned into pET52b. Recombinant RSV 254 
G
157-197
 was expressed overnight in E. coli BL21(DE3) at 18°C. E. coli cells were lysed 255 
by ultrasonication in 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, and 25 mM imidazole 256 
(buffer A) containing 2 μM MgCl2, benzonase, and protease inhibitors. RSV G157-197 was 257 
purified from soluble lysates by HisTrap FF affinity chromatography and eluted with a 258 
gradient into buffer B (buffer A containing 500 mM imidazole).  259 
 260 
Formation and structure determination of the Fab 3G12-RSV G
157-197 
complex. 261 
Purified RSV G
157-197
 was mixed in 2-molar excess with purified Fab 3G12, incubated for 262 
1 hour at 4° C, and purified by Superdex 75 size-exclusion chromatography in 10 mM 263 
Tris-HCl pH 8.0 and 150 mM NaCl. The Fab 3G12-RSV G
157-197 
complex was 264 
concentrated to 15 mg/ml. Crystals were grown by hanging drop vapor diffusion at 22°C 265 
with a well solution of 1.8 M Ammonium Sulfate and 100 mM Sodium acetate trihydrate 266 
(pH 4.4). Crystals were transferred into a cryoprotectant solution of 2.0 M Ammonium 267 
Sulfate, 100 mM Sodium acetate trihydrate (pH 4.4) and 25% glycerol and flash-frozen 268 
in liquid nitrogen. Diffraction data were collected at cryogenic temperature at the 269 
Advanced Light Source on beamline 8.3.1 using a wavelength of 1.11503 Å. Diffraction 270 
data from a single crystal were processed with iMosflm (72) and Aimless (73) (Table 1). 271 
The Fab 3G12-RSV G
157-197
 complex structure was solved by molecular replacement 272 
with the Fab from PDB 5K59 and the program PHASER (74), and the structure was 273 
refined and manually rebuilt using PHENIX (75) and Coot (76), respectively (Table 1). 274 
 275 
Expression and purification of RSV G
ecto 
and RSV G
ecto
 F170P. A codon-optimized 276 
synthetic gene encoding RSV G (strain A2) amino acids 64 to 298 (UniProtKB entry 277 
P03423) was cloned into pCF in-frame with an N-terminal CCR5 signal sequence and C-278 
terminal His-tag and Twin-Strep purification tags. The F170P mutation was introduced 279 
by Phusion site-directed mutagenesis and verified by Sanger sequencing. Recombinant 280 
RSV G
ecto
 and RSV G
ecto
 F170P were produced by transient-transfection in HEK293F 281 
cells with Effectene Transfection Reagent (Qiagen). After 5 days, cell media was 282 
supplemented with BioLock (IBA) and 20 mM Tris-HCl pH 8.0 and 0.22um-filtered. 283 
RSV G
ecto
 and RSV G
ecto
 F170P were batch purified from media with Strep-Tactin resin 284 
(IBA), washed, and eluted with Strep-Tactin elution buffer (50 mM Tris pH 8.0, 150mM 285 
NaCl, 1mM EDTA, 2.5mM desthiobiotin).  RSV G
ecto
 and RSV G
ecto
 F170P were 286 
concentrated and dialyzed into PBS using 10 kDa spin concentrators. Protein purity was 287 
evaluated by SDS-polyacrylamide gel electrophoresis. 288 
 289 
Binding affinity analyses. An Octet RED96e biolayer interferometry instrument was 290 
used to evaluate binding of bnmAbs 3G12 and 3D3 to RSV G
ecto
 and RSV G
ecto
 F170P. 291 
Antibody 3G12 or 3D3 at 1 μg/ml in Octet buffer (phosphate buffered saline pH 7.4, 292 
0.05% Tween-20, 1% BSA) was loaded onto Anti-Human IgG Fc Capture (AHC) 293 
biosensors, and two-fold serially diluted RSV G
ecto
 or RSV G
ecto
 F170P, from 40 nM to 294 
0.625 nM, was assessed for binding. Red lines are the fit of a global association and 295 
dissociation with a 1:1 model, with at least 5 curves used to determine binding on- and 296 
off-rates and to calculate dissociation constants.  297 
 298 
Accession code. Coordinates and structure factors have been deposited in the Protein 299 
Data Bank under accession code 6UVO.  300 
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FIGURE LEGENDS  575 
 576 
 577 
Fig. 1. Crystal structure of the Fab 3G12-RSV G
157-197
 complex. (A) Schematic of the 578 
RSV G glycoprotein from RSV strain A2, including the transmembrane region (TM), 579 
CCD, and the cysteine noose (Cys noose). Met48 is the alternate initiation site for the 580 
production of soluble RSV G. Predicted N- and O-linked glycans are shown by red “Y” 581 
and blue “O,” respectively. Below is a sequence logo of residues 160-197 of the RSV G 582 
CCD, revealing the sequence conservation across strains RSV A, RSV B, RSV L, and 583 
RSV 1-8. (B) Overall views of antibody 3G12 heavy chain (dark grey) and light chain 584 
(light grey) bound to RSV G
157-197
 (cyan, with disulfides in yellow). (C) Detailed views 585 
of interactions between antibody 3G12 with RSV G CCD, with the same viewpoints as in 586 
panel B. Hydrogen bonds are shown as dashes. Heavy-chain CDRs (HCDR1-3) and light-587 
chain CDRs (LCDR1 and 3) are labeled. 588 
 589 
Fig. 2. Comparison of known RSV G CCD epitopes and structures. Epitope amino acids 590 
interacting with antibodies are colored as follows: 3G12 (blue), CB002.5 (gold), 3D3 591 
(green), CB017.5 (magenta), and 2D10 (cyan). Bottom panels are rotated 180 degrees 592 
around the y-axis compared to top panels. Epitope amino acids were determined by the 593 
PDBePISA server and are written below each structure. 594 
 595 
Fig. 3. Differences in bnmAb 3G12 and bnmAb 3D3 binding to RSV G
ecto 
F170P. (A) 596 
Coomassie-stained SDS-polyacrylamide gel of RSV G
ecto
 (Wild-Type) and RSV G
ecto
 597 
F170P (F170P). Molecular weight (MW) ladder values are labeled in kilodaltons. (B) 598 
Structure of RSV G CCD when bound to bnmAb 3D3 (top) and bnmAb 3G12 (bottom). 599 
F170 is colored red. (C) Biolayer interferometry traces (blue) and curve fits (red) for 600 
binding of bnmAb 3D3 (top) and bnmAb 3G12 (bottom) to RSV G
ecto
 and RSV G
ecto
 601 
F170P. Concentrations of G
ecto
 used for each trace are shown. The vertical red line 602 
indicates the transition of the biosensors from the association step to the dissociation step. 603 
Binding on-rates, off-rates, dissociation constants, and curve fit statistics are shown in 604 
Table 2. 605 
 606 
Fig. 4. Proposed model relating antigenic site flexibility, antibody response diversity to 607 
that site, and potential for virus neutralization escape at that site. 608 
Table 1.  Crystallographic data collection and refinement statistics 609 
 610 
 Fab 3G12-RSV G157-197 
PDB code 6UVO 
Data collection
a,b
  
Space group P3121 
Cell dimensions  
    a, b, c (Å) 139.33 139.33 94.77 
    α, β, γ ()  90, 90, 120 
Resolution (Å) 74.53 - 2.90 (3.00 - 2.90) 
Total no. reflections 
No. unique reflections 
Rmerge
c 
93,208 (14,475) 
23,682 (3,763) 
0.097 (0.641) 
I / σ(I) 9.4 (1.9) 
Completeness (%) 99.5 (99.5) 
Redundancy 3.9 (3.8) 
CC1/2
d
 0.993 (0.601) 
 
Refinement 
 
Resolution (Å) 74.53 - 2.90 
No. reflections 23,665  
Rwork / Rfree
e 0.193/ 0.209 
No. atoms  
    Protein 3,595 
    Ligand/ion 0 
    Water 0 
B-factors (Å
2
)  
    Protein: bnmAb 
    Protein: RSV G 
62 
76 
    Ligand/ion 0 
R.m.s. deviations  
    Bond lengths (Å) 0.015 
    Bond angles () 
Ramachandran (%) 
    Favored 
    Allowed 
    Outliers 
2.067 
 
95.7 
4.3 
0 
a Data from one crystal was used. 611 
b Values in parentheses are for highest-resolution shell. 612 
c Rmerge = Σ|(I - <I>)| / Σ(I), where I is the observed intensity. 613 
d CC1/2 = Pearson correlation coefficient between random half-datasets. 614 
e Rwork = Σ||Fo| - |Fc|| / Σ|Fo| for all data except 5%, which were used for Rfree calculation 615 
  616 
Table 2.  Biolayer interferometry binding studies
a
 617 
 618 
Sample bnmAb KD (pM) ka (x10
5 M-1s-1) kd (x10
-4 s-1) R2 
RSV G ecto 3D3 202 (1) 8.73 (0.02) 1.77 (0.01) 0.998 
RSV G ecto F170P 3D3 264 (1) 6.23 (0.01) 1.65 (0.01) 0.999 
RSV G ecto 3G12 423 (1) 5.27 (0.01) 2.23 (0.01) 0.999 
RSV G ecto F170P 3G12 N.B.a - - - 
a KD, binding dissociation constant. ka, on-rate. kd, off-rate. R
2, curve fit statistic. N.B., no binding 619 
observed. Values in parentheses are the standard error. 620 




